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Unfractionated and  
low-Molecular-Weight heparin and 
the Phosphodiesterase inhibitors, 
iBMX and cilostazol, Block Ex Vivo 
equid herpesvirus Type-1-induced 
Platelet activation
Tracy Stokol*, Priscila B. S. Serpa, Muhammad N. Zahid and Marjory B. Brooks
Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, USA
Equid herpes virus type-1 (EHV-1) is a major pathogen of horses, causing abortion 
storms and outbreaks of herpes virus myeloencephalopathy. These clinical syndromes 
are partly attributed to ischemic injury from thrombosis in placental and spinal vessels. 
The mechanism of thrombosis in affected horses is unknown. We have previously shown 
that EHV-1 activates platelets through virus-associated tissue factor-initiated thrombin 
generation. Activated platelets participate in thrombus formation by providing a surface 
to localize coagulation factor complexes that amplify and propagate thrombin gener-
ation. We hypothesized that coagulation inhibitors that suppress thrombin generation 
(heparins) or platelet inhibitors that impede post-receptor thrombin signaling [phospho-
diesterase (PDE) antagonists] would inhibit EHV-1-induced platelet activation ex vivo. 
We exposed platelet-rich plasma (PRP) collected from healthy horses to the RacL11 
abortigenic and Ab4 neuropathogenic strains of EHV-1 at 1 plaque-forming unit/cell in 
the presence or absence of unfractionated heparin (UFH), low-molecular-weight heparin 
(LMWH) or the PDE inhibitors, 3-isobutyl-1methylxanthine (IBMX), and cilostazol. We 
assessed platelet activation status in flow cytometric assays by measuring P-selectin 
expression. We found that all of the inhibitors blocked EHV-1- and thrombin-induced 
platelet activation in a dose-dependent manner. Platelet activation in PRP was maximally 
inhibited at concentrations of 0.05 U/mL UFH and 2.5 μg/mL LMWH. These concentra-
tions represented 0.1–0.2 U/mL anti-factor Xa activity measured in chromogenic assays. 
Both IBMX and cilostazol showed maximal inhibition of platelet activation at the highest 
tested concentration of 50 μM, but inhibition was lower than that seen with UFH and 
LMWH. Our results indicate that heparin anticoagulants and strong non-selective (IBMX) 
or isoenzyme-3 selective (cilostazol) PDE antagonists inhibit ex vivo EHV-1-induced 
platelet activation. These drugs have potential as adjunctive therapy to reduce the 
serious complications associated with EHV-1-induced thrombosis. Treatment trials are 
warranted to determine whether these drugs yield clinical benefit when administered to 
horses infected with EHV-1.
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inTrODUcTiOn
Equid herpesvirus type-1 (EHV-1) is a major contagious patho-
gen of horses, causing individual cases and outbreaks of respira-
tory disease worldwide. The most severe clinical consequences 
of EHV-1 infection are abortion and a neurologic syndrome, 
called equine herpes myeloencephalopathy (EHM). Horses suf-
fering from EHM are frequently euthanized due to the severity 
of neurologic symptoms and performance horses affected with 
milder neurologic disease often have reduced performance (1). 
Abortion and EHM are thought to result from EHV-1 infection of 
placental and neural tissue, with the virus reaching these tissues 
through a cell-associated viremia and subsequent endothelial 
infection, vasculitis, and tissue invasion (2–5). Pathologic studies 
in experimentally and naturally infected horses have revealed 
the presence of thrombi in placental and neural vessels (2, 5, 6). 
Hypoxic damage from thrombosis likely contributes substantially 
to the tissue injury that results in abortion and EHM.
Horses experimentally infected with EHV-1 have high 
d-dimer concentrations during the viremic phase of infection 
(7). d-dimer is the terminal breakdown product of cross-linked 
fibrin and high concentrations support a systemic hypercoagu-
lable and prothrombotic state (8). The cause of the documented 
hypercoagulability and thrombosis in EHV-1-infected horses is 
unknown, but is likely multifactorial, involving release or upreg-
ulation of procoagulants, such as tissue factor, with endothelial 
injury or vasculitis. We have also previously shown that EHV-1 
induces tissue factor expression in equine monocytes (9). 
Because tissue factor is the main activator of coagulation in vivo 
(10), upregulated expression of tissue factor on monocytes 
could be one trigger of the hypercoagulable state. We have also 
recently shown that EHV-1 alone can activate coagulation and 
generate thrombin in equine plasma ex vivo (11). Thrombin 
generation was initiated by tissue factor expressed on the virus, 
with the tissue factor presumably being incorporated into the 
virus envelope during budding from the propagating cell line. 
We also found that the virus-generated thrombin activated 
platelets in equine platelet-rich plasma (PRP), causing α-granule 
exteriorization, characterized by surface expression of the 
α-granule protein, P-selectin, and release of membrane-derived 
microparticles (11).
Platelets play an important role in thrombosis. Once activated, 
they not only form dense fibrinogen-bound aggregates but also 
mobilize lipid membranes, providing a phosphatidylserine-rich 
outer membrane surface that catalyzes thrombin generation (so-
called platelet procoagulant activity) (12). In accordance with this, 
we have found that addition of platelets to equine platelet-poor 
plasma (PPP)-containing EHV-1 generated more thrombin than 
the virus in PPP alone (11). Activated platelets also help recruit 
and bind leukocytes to the developing thrombus by forming 
adhesive bonds between platelet surface-expressed P-selectin and 
leukocyte-expressed P-selectin glycoprotein ligand-1 (13). Once 
bound, leukocytes promote thrombus formation by expressing 
tissue factor (monocytes) or undergoing NETosis (neutrophil 
extracellular traps) (10, 14). Thus, inhibiting platelet activation 
and particularly P-selectin expression could substantially reduce 
thrombus formation and may provide therapeutic or prophylactic 
options for horses at-risk of abortion and EHM due to EHV-1 
infection.
We recently performed a clinical trial in horses to determine 
whether traditional antiplatelet drugs, including aspirin and 
the ADP receptor antagonist, clopidogrel, could inhibit EHV-
1-induced platelet activation. We also tested the non-specific 
phosphodiesterase (PDE) inhibitors, theophylline and pentoxi-
fylline, which are weak blockers of platelet signaling downstream 
of receptor activation (15). We found that none of these drugs, 
when given to horses at standard therapeutic doses, were effective 
against EHV-1-induced platelet activation ex vivo.1 This finding 
can be attributed to the inability of these antiplatelet drugs to 
prevent thrombin generation, which is the primary mechanism 
underlying the EHV-1-induced activation response. Our results 
indicate a need to find inhibitors that effectively block the 
thrombin-mediated platelet-activating effects of EHV-1.
We hypothesized that inhibition of thrombin generation or 
stronger and more selective inhibition of thrombin-mediated 
platelet signaling could block EHV-induced platelet activation. 
To test this hypothesis, we added anticoagulant and antiplatelet 
agents to PRP obtained from healthy horses and then meas-
ured platelet activation after ex vivo exposure to EHV-1. Flow 
cytometric detection of α-granule release based on surface 
P-selectin expression was used as a marker of platelet activa-
tion. To inhibit thrombin generation, we tested unfractionated 
heparin (UFH) and low-molecular-weight heparin (LMWH), 
anticoagulants that are used clinically for thromboprophylaxis in 
horses (16, 17). To inhibit thrombin-induced platelet signaling, 
we tested the strong competitive non-selective PDE inhibitor, 
3-isobutyl-1methylxanthine (IBMX) (18), and the selective PDE 
isoenzyme 3 (PDE3) inhibitor, cilostazol (15). High concentra-
tions of intraplatelet cAMP and cGMP act as a brake against 
agonist-initiated signaling that culminates in platelet activation. 
Phosphodiesterases normally direct the hydrolysis of cAMP, 
maintaining low intracellular cAMP and cGMP concentrations, 
which then permits signaling induced by various agonists, includ-
ing thrombin, adenosine diphosphate, and  platelet-activating 
factor. PDE inhibitors increase intracellular cAMP and cGMP 
concentrations and block platelet activation downstream of 
agonist receptor engagement (15, 18–21). Several isoenzymes of 
PDE have been identified in horses, of which PDE3 has been 
ascribed the main role in blocking platelet activation secondary 
to agonists (18). We chose IBMX and cilostazol because they 
effectively inhibit P-selectin expression and platelet aggrega-
tion in agonist-stimulated equine (IBMX) (18, 19) and human 
platelets (22) ex vivo, respectively.
MaTerials anD MeThODs
Virus isolation
The RacL11 [originally isolated from an aborted fetus (23)] and 
Ab4 [originally isolated from a gelding with equine herpesvirus 
1 Hernandez D, Yeo WM, Brooks MB, Ness SL, Divers TJ, Stokol T. Effects of various 
antiplatelet drugs on ex vivo platelet activation induced by equine herpesvirus type 
1. Am J Vet Res (2016).
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myeloencephalopathy (6)] strains of EHV-1 were purified from 
rabbit kidney 13 cell lysates using sucrose gradient ultracentrifu-
gation, as previously described (11). Purified virus was reconsti-
tuted in phosphate-buffered saline (PBS) and frozen at −80°C in 
aliquots with single use thaws. Virus stocks were titered using a 
standard plaque assay with rabbit kidney 13 cells.
Blood sample collection and Preparation 
of Platelet-rich and Platelet-Poor Plasma
Both PRP and PPP were prepared from 4.5 mL of blood collected 
directly into a 6-mL syringe containing 0.5 mL 3.8% citrate from 
the jugular vein of clinically healthy horses housed at the Cornell 
University Equine Research Park as previously described (11). 
The horses consisted of 16 mares and 2 stallions. None of the 
mares were pregnant or in the first month of lactation. In brief, 
PRP was prepared within 15–30 min of collection by low-speed 
centrifugation (250  ×  g, 21°C, 10  min) of the leukocyte-PRP 
resulting from gravity sedimentation of erythrocytes for 20 min 
at 20–23°C (room temperature). A platelet count was performed 
on the resulting PRP with an automated hematology analyzer 
(ADVIA 2120, Siemens Healthcare Diagnostics Inc., Tarrytown, 
NJ, USA). Platelet-poor plasma was prepared by high-speed 
centrifugation of residual PRP (15,000 g, 20–23°C, 5 min). The 
sample collection protocol was approved by the Institutional 
Animal Care and Use Committee at Cornell University (#2007-
0086), which follows several federal and state guidelines.
Platelet exposure to Virus and inhibitors
The PRP was diluted (1 × 106/mL, final concentration) in flow 
buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM calcium chloride, 
pH 7.4, with 20  mM supplemental glycine–proline–arginine–
proline to inhibit fibrin polymerization) to a final volume of 
100 μL. Platelets were exposed to each virus strain at 1 plaque-
forming unit (PFU)/cell for 10 min at 37°C, with PBS and bovine 
thrombin (0.15 U/mL; 20–30 nM, Sigma-Aldrich, St. Louis, MO, 
USA) as negative and positive controls of platelet activation, 
respectively. Inhibitors were added to the buffer before addi-
tion of PRP. The following inhibitors were used: UFH (Sagent 
Pharmaceuticals, Schaumburg, IL, USA) at final concentrations 
ranging from 0.02 to 2 U/mL; LMWH (powder, Galen Laboratory 
Supplies, Middletown, CT, USA) at final concentrations ranging 
from 0.1 to 5.0 μg/mL; IBMX (Sigma-Aldrich) at final concentra-
tions ranging from 5 to 50 μM; and cilostazol (Sigma-Aldrich) 
at final concentrations ranging from 1 to 50 μM. For UFH and 
LMWH, PBS was the vehicle control, whereas for the PDE inhibi-
tors, dimethylsulfoxide (DMSO) was the vehicle control. The PRP 
from individual horses (or experiments) was not spiked with all 
drug concentrations, however, negative and positive controls 
were included in each experiment and a minimum of three rep-
licates (three different horses) of each concentration was tested. 
In two horses, the thrombin positive control did not work due to 
a dilutional error or the inhibitor was mistakenly not added to 
the PBS control. The data for these controls were not included 
in the provided results. Chondroitin sulfate (5 μg/mL, type A 
sodium salt from bovine trachea, Sigma-Aldrich) is a negatively 
charged polysaccharide and was used as a negative control for 
UFH and LMWH. For LMWH, the higher tested concentrations 
(2.5–5.0 μg/mL) were equivalent to the total maximal reported 
plasma concentrations (0.24–0.45 U/mL) obtained with pharma-
cokinetic studies in horses using doses of 40–100 U/mL (24). For 
cilostazol, concentrations were based on that previously used to 
inhibit P-selectin expression in human platelets after thrombin 
or collagen stimulation (22). For IBMX, concentrations were 
selected based on previous studies with human (21) and equine 
(18, 19) platelets. We chose cilostazol over trequinsin, a PDE3 
inhibitor that has been used in previous studies in horses (18–20), 
due to cost.
Flow cytometric Detection of Platelet 
activation
Flow cytometric measurement of P-selectin on platelet surfaces, 
indicating degranulation of α-granules, was used as an indicator 
of platelet activation, as we have previously described (11). In 
brief, after 10  min of exposure to virus or activation controls, 
platelets were incubated with an antibody against P-selectin 
conjugated to Alexa-647 or allophycocyanin (33.3 ng/mL final 
concentration, clone Psel.KO.2.7, Novus Biologicals, Littleton, 
CO, USA) for 10 min, followed by quench dilution (400 μL) in 
flow buffer. The samples were then analyzed with a flow cytom-
eter (FACSCalibur™, BD Biosciences, Franklin Lakes, NJ, USA), 
gating platelets on their characteristic forward and side scatter. 
The percentage of P-selectin-positive platelets was then deter-
mined from histogram plots of the gated platelets (Figure 1A), 
using commercial software (FlowJo v10, FlowJo LLC, Ashland, 
OR, USA).
Measurement of anti-Factor Xa activity
To relate the concentrations of UFH and LMWH added to PRP 
to target anticoagulant effects of heparin measured by factor Xa 
inhibitory activity (anti-Xa), PPP samples collected from the 
study horses were spiked with the drugs and frozen at −20°C until 
batch assay. Anti-Xa activities were measured using a commercial 
kit (Liquid anti-Xa, Diagnostica Stago) and an automated coagu-
lation analyzer (STA Compact, Diagnostica Stago, Parsippany, 
NJ, USA). The assay is a one-step competitive inhibition assay, 
configured with a bovine factor Xa reagent and a chromogenic 
substrate of factor Xa. The color change of the reaction mixture 
is inversely proportional to the heparin concentration in the 
test plasma (expressed as units per milliliter anti-Xa). The assay 
calibrators contain known concentrations of UFH or LMWH 
in human plasma (STA-calibrator HBPM/LMWH, Diagnostica 
Stago). Routinely used target anti-Xa activities in horses (based 
on heparin therapy in humans) are 0.1–0.2  U/mL anti-Xa for 
prophylaxis and 0.3–0.7 U/mL anti-Xa for therapy (24).
statistical analysis
Data were non-parametric and results are expressed as median, 
with range as applicable. Graphical displays are column charts 
with medians and superimposed individual data points. For many 
experiments, obtained results were consistent between horses but 
could not be statistically compared due to the number of repeats 
(i.e., less than six different horses per experiment). Thus only 
FigUre 1 | Unfractionated heparin (UFh) inhibits ehV-1-induced platelet activation, as measured by P-selectin expression with flow cytometry.  
 (Continued)
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TaBle 1 | Median and range of anti-factor Xa activity in equine platelet-
poor plasma spiked with various doses of unfractionated heparin (UFh).
UFh dose  
(U/ml)
anti-Xa activity (U/ml) number of  
horses
Median range
0 0 0–0 9
0.02 0 0–0 6
0.05 0 0–0 4
0.1 0 0–0.1 3
0.2 0.1 0.1–0.2 5
0.5 0.3 0.2–0.6 4
1 0.7 0.6–0.8 4
2 1.5 1.4–2.9 5
FigUre 2 | low-molecular-weight heparin (lMWh) inhibits  
ehV-1-induced platelet activation, as measured by P-selectin 
expression with flow cytometry. P-selectin expression was quantified in 
response to thrombin (0.15 U/mL, light gray columns) or RacL11 (dark gray 
columns) and Ab4 (black columns) strains of EHV-1 at 1 PFU/cell as the 
percentage of gated platelets in the absence or presence of increasing 
concentrations of LMWH (0.1–2.5 μg/mL) (n = 3–9). Complete inhibition 
was observed at 2.5 μg/mL (*P values compared to no LMWH, Wilcoxon 
matched pairs sign rank) and 5 μg/mL (not shown). No activation was seen 
with the PBS control in the absence or presence of LMWH (only highest 
dose shown). Columns represent medians with superimposed individual 
data points.
(a) Platelets were gated (R1) in a forward versus side scatter plot (left panel) and the percentage of P-selectin-positive cells in the gated region was measured 
(marker or M1 region) using histogram plots of P-selectin fluorescence (right panel). In the absence of UFH, thrombin (0.15 U/mL) and both RacL11 and Ab4 strains 
of EHV-1 at 1 PFU/cell activated platelets. Activation was evident as lengthening and narrowing of the platelet event cloud, with some microvesiculation (arrows) and 
>90% platelets expressing P-selectin. (B) In the presence of 2 U/mL UFH, inhibition of platelet activation is seen in forward versus side scatter (left panel) and 
histogram plots of P-selectin expression (right panel) in gated platelets (R1) exposed to thrombin and both viruses. No changes are seen in the PBS control with or 
without UFH. Residual small events (<101 forward scatter units) in the virus-exposed samples in the presence of UFH likely represent aggregated virus particles. 
Images in (a,B) are representative of one horse. Note that EHV-1-induced activation in this horse was not completely abolished in the presence of heparin, possibly 
due to mild “preactivation” of platelets (4% P-selectin expression in PBS control). (c) Quantification of the median percentage of P-selectin-positive platelets 
(columns), with superimposed individual data points, in response to thrombin (light gray columns) or both strains of EHV-1 (RacL11, dark gray columns; Ab4, black 
columns) in the absence or presence of 2 U/mL UFH (n = 6–7). *Numbers shown are P values (Wilcoxon matched pairs sign rank). (D) A heparin dose titration curve 
showed consistent inhibition of thrombin (light gray columns) and EHV-1-induced platelet activation at 0.05 U/mL (RacL11, dark gray columns; Ab4, black columns; 
n = 3–10). Columns represent medians with superimposed individual data points.
FigUre 1 | continued
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selected results (those with sufficient number of replicates) were 
compared with a Wilcoxon match paired sign rank test. Alpha 
was set at 5% (two-tailed).
resUlTs
We first determined whether UFH could inhibit EHV-1-induced 
platelet activation. We found that UFH at a concentration of 
2 U/mL spiked into PRP inhibited platelet activation induced by 
both strains of EHV-1 at 1 PFU/cell and by the positive control 
treatment of 0.15 U/mL of thrombin. This inhibition was evident 
by minimal changes in the platelet event cloud on flow cytomet-
ric forward versus side scatter plots and a marked significant 
reduction in platelet P-selectin expression on histogram plots 
(Figures  1A–C). When spiked into equine PPP, 2  U/mL UFH 
yielded anti-Xa activities above target range therapeutic anti-Xa 
activity (0.3–0.7 anti-Xa U/mL) (Table  1). To relate the UFH 
concentrations that inhibited EHV-1-induced platelet activation 
with target range anticoagulant anti-Xa activities, we performed 
a dose-response series. We found that EHV-1-induced platelet 
activation was inhibited by UFH in PRP of all tested horses at 
a concentration of 0.05  U/mL, with variable inhibition among 
individuals at UFH concentrations of 0.02  U/mL. Some dif-
ferences were noted between virus strains at the lowest UFH 
concentrations (Figure 1D). A concentration of 0.1 U/mL UFH 
was required to consistently inhibit thrombin-induced platelet 
activation, with PRP from some horses showing partial inhibition 
at 0.05 U/mL UFH (Figure 1D). Anti-Xa activity was detectable 
in the PPP of two out of three horses spiked with 0.1 U/mL UFH 
and was generally within target range of 0.3–0.7 anti-Xa U/mL at 
UFH concentrations ranging from 0.2 to 1 U/mL UFH (Table 1). 
The EHV-1-stimulated PRP of one horse demonstrated an 
“escape” from inhibition with up to 8 and 16% P selectin expres-
sion persisting in RacL11- and Ab4-activated reactions contain-
ing increasing concentrations of UFH (Figure  1D). A  similar 
“escape” was not seen after thrombin stimulation in this horse, 
arguing against a dilution error. The reason for this finding is 
unclear (the other inhibitors were not tested in this horse).
We next tested whether various concentrations of LMWH 
could inhibit EHV-1-induced platelet activation. We found that 
inhibition of EHV-1-induced platelet activation began at 0.5 μg/
mL and was complete at 2.5 μg/mL LMWH for both strains. Virus 
strain-dependent differences were seen in the inhibitory activity 
TaBle 2 | Median and range of anti-factor Xa activity in equine platelet-
poor plasma spiked with various doses of low-molecular-weight heparin 
(lMWh).
lMWh dose  
(μg/ml)
anti-Xa activity (U/ml) number  
of horses
Median range
0 0 0–0 5
0.1 0 0–0 2
0.5 0 0–0 3
1 0 0–0.1 3
2.5 0.1 0.1–0.6 4
5.0 0.3 0.2–0.3 3
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of LMWH, with RacL11 showing a trend toward enhanced sus-
ceptibility to low-dose LMWH inhibition than Ab4 (Figure 2). 
Target prophylactic anti-Xa activities were only achieved in all 
horses at 2.5 μg/mL LMWH (Table 2), with only one out of three 
tested horses achieving a target therapeutic anti-Xa activity at this 
concentration. At the highest tested dose of 5 μg/mL, which com-
pletely blocked EHV-1- and thrombin-induced activation (not 
shown), target therapeutic concentrations were obtained in two 
out of three tested horses (Table 1). In contrast to UFH, LMWH 
showed a trend toward stronger inhibition of thrombin-induced 
activation compared to the activation caused by both virus 
strains, with inhibition of thrombin activation starting at 0.1 μg/
mL LMWH and being almost complete at 0.5 μg/mL (Figure 2). 
Exposure of PRP to chondroitin sulfate, a glycosaminoglycan with 
no anticoagulant action used as a negative control for heparin, 
had no effect on thrombin- or EHV-1-induced platelet activation 
(Figure S1 in Supplementary Material).
We then tested the strong non-selective PDE inhibitor, IBMX, 
and the selective PDE3 inhibitor, cilostazol, for their inhibitory 
effect on EHV-1-induced platelet activation. We found that both 
inhibitors reduced platelet activation induced by EHV-1 and our 
thrombin positive control, with IBMX showing a trend toward 
a stronger effect than cilostazol at similar concentrations. There 
was a trend for thrombin stimulation to be inhibited by a greater 
degree than virus exposure at the same concentration of PDE 
inhibitors (Figures 3A,B). The presence of DMSO vehicle or PDE 
inhibitors did not enhance platelet activation in negative (PBS) 
control reactions. We found that the DMSO vehicle displayed a 
mild, but not significant, suppressive effect on activation induced 
by EHV-1 and thrombin (Figures 3A,B). We also noticed that the 
DMSO vehicle and both PDE inhibitors caused microvesicula-
tion or fragmentation of platelets in the presence of EHV-1, but 
not thrombin (Figure 3C).
DiscUssiOn
In this ex vivo study, we found that anticoagulants that inhibit 
thrombin generation (UFH, LMWH) and antiplatelet drugs 
that inhibit signaling pathways downstream of agonist receptors 
(IBMX, cilostazol) block EHV-1-induced platelet activation, as 
measured by platelet P-selectin expression. Because ischemic 
injury from thrombosis contributes to the EHV-1-associated 
clinical syndromes of abortion and EHM and platelets are crucial 
for thrombus formation, our results suggest that these drugs may 
be useful to prevent or ameliorate EHV-1-induced thrombosis 
in at-risk horses. Notably, EHV-1-induced platelet activation 
at 1  PFU/cell was inhibited by UFH doses that did not yield 
detectable anti-Xa activity when spiked into equine PPP. Similar 
results were seen with LMWH, although complete inhibition of 
EHV-1-induced activation required LMWH doses that yielded 
higher anti-Xa activities (0.1–0.2 U/mL). These data suggest that 
low doses of both types of heparin may be sufficient to inhibit 
EHV-1-induced platelet activation in vivo. However, the number 
of virions that platelets may be exposed to in vivo is unknown. It 
is possible that at sites of high virus replication, such as infected 
endothelial cells, platelets may be exposed to more than 1 PFU/
cell and higher circulating levels of heparin anti-Xa activity may 
be required.
We observed a trend for UFH to have a stronger inhibitory 
effect on EHV-1- than thrombin-induced platelet activation. This 
differential inhibitory effect was most apparent at the lower UFH 
concentrations of 0.02 and 0.05 U/mL. A potential explanation 
for this observation is that heparin may inhibit EHV-1 binding 
to platelets, as reported for Dengue virus (25). Since the envelope 
glycoproteins gB and gC of equine α-herpesviruses, including 
EHV-1 and EHV-4, can bind to heparin-like glycosaminoglans 
on cells, heparin can be used to block virus binding to cells 
(26–28). We have previously found that EHV-1 does associate 
with platelets (11) and speculate that this association is mediated 
through the virus tethering to heparin-like glycosaminoglycans 
via gB and gC, although other virus-platelet receptor interactions 
may be involved. Binding of tissue factor-expressing virions to 
a phosphatidylserine-rich cell surface expressed on activated 
platelets would substantially boost thrombin generation, as we 
have shown when we added virions to equine PRP in a thrombin 
generation assay (11). Based on these previous observations, we 
speculate that UFH may be inhibiting virus attachment to platelet 
surfaces, limiting thrombin generation to “free” or unattached 
virions, which would then generate less thrombin overall. This 
effect may only become evident at lower UFH concentrations, 
which are insufficient to completely block any free thrombin 
generated by the virus. An alternative explanation is that EHV-1, 
at 1  PFU/cell, is generating less thrombin in equine PRP than 
0.15  U/mL of exogenous thrombin. However, this explanation 
is not supported by our results with LMWH, which showed a 
stronger inhibitory effect for thrombin- than EHV-1-induced 
platelet activation with LMWH at doses less than 2.5  μg/mL. 
A similar trend was seen with the PDE inhibitors, IBMX, and 
cilostazol. The latter data suggest that EHV-1 is generating more 
thrombin than the exogenously added thrombin in our positive 
control, which is then insufficiently inhibited by lower LMWH 
or PDE inhibitor concentrations. It is also possible that LMWH, 
being of shorter length and less charge, is a less effective inhibitor 
of virus binding to heparin-like glycosaminoglycans than UFH. 
Chondroitin sulfate, which is negatively charged like heparin 
and is used as a negative control for heparin in virus-cell binding 
studies (25), had no effect on EHV-1-induced platelet activation.
We observed some differences between the 2 tested virus 
strains in the degree of inhibition in response to the various 
drugs in the same horse. For LMWH at 0.5–1 μg/mL, there was 
a trend toward a larger degree of inhibition for RacL11- than 
FigUre 3 | The phosphodiesterase inhibitors, iBMX and cilostazol, reduce ehV-1-induced platelet activation, as measured by P-selectin 
expression with flow cytometry. 
(Continued)
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FigUre 3 | continued  
P-selectin expression in response to thrombin (0.15 U/mL, light gray columns) or RacL11 (dark gray columns) and Ab4 (black columns) strains of EHV-1 at 1 PFU/
cell was quantified as the percentage of gated platelets in the absence or presence of increasing concentrations of (a) IBMX (5–50 μM) (n = 3–4) or (B) cilostazol 
(cilo, 1–50 μM) (n = 3–9). Both drugs inhibited activation induced by thrombin and both virus strains, to varying degrees. The DMSO vehicle control mildly 
suppressed the activation responses. No activation was seen with the PBS control in the absence or presence of either drug (only highest dose of drug 
shown). Bars represent medians with superimposed individual data points. (c) Forward versus side scatter plots show the inhibitory effects of IBMX as well as 
the platelet fragmentation or vesiculation that occurred in the presence of the DMSO vehicle and virus (arrows), but not thrombin. A similar vesiculation effect 
was seen with cilostazol (not shown). Increased small events (<101 forward scatter units) in the virus alone-exposed samples represent a combination of 
microvesicles or platelet fragments and aggregates of virus particles. The number of replicates was insufficient to perform statistical analysis.
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Ab4-induced activation. This observation is consistent with our 
previous finding that Ab4 generates more thrombin ex vivo at the 
same PFU/cell than RacL11 (11). However, the opposite finding 
was true for the lower concentrations of UFH and cilostazol, 
whereas a clear pattern was not apparent with IBMX, the strong 
PDE inhibitor. The reason for these within horse differences 
in the inhibitory effect of the drugs against platelet activation 
induced by the two virus strains is unclear. Since heparin may 
inhibit virus binding as well as thrombin generation and cilosta-
zol is a post-signaling antagonist, it is possible that there are virus 
strain-dependent differences in binding to platelets, as we have 
speculated previously (11).
Substantial variability was also evident between individual 
horses in the degree of suppression of EHV-1-induced platelet 
activation with all inhibitors. This can likely be explained by 
individual differences in coagulation factor concentrations, 
which are required by the virus to generate thrombin. A similar 
biological variability in the suppression of thrombin generation 
by various drugs, including heparin, has been reported in healthy 
human volunteers (29). This variability can be partly explained by 
documented differences between healthy individuals in throm-
bin generation (30), potentially due to variable coagulation factor 
concentrations and platelet procoagulant activity (31). We have 
seen similar variability in thrombin generation in horses (unpub-
lished observations). Inter-horse variability was also observed 
in the suppressive effect of the drugs on thrombin-induced 
platelet activation. This could potentially be explained by the 
exogenous thrombin triggering amplification of the horse’s own 
coagulation factors in the recalcified citrated plasma. However 
platelet-dependent differences in response to agonists, such as 
differential calcium signaling or other genetic or environmental 
factors (32, 33), may also explain the observed variability between 
horses in the response to the inhibitors.
The PDE inhibitors, IBMX and cilostazol, inhibited EHV-
1- and thrombin-induced platelet activation in equine PRP. 
At equivalent concentrations, IBMX generally had a stronger 
inhibitory effect than cilostazol on EHV-1 and thrombin-induced 
platelet activation. This is likely because IBMX is a strong non-
selective PDE inhibitor (18), whereas cilostazol is a selective 
PDE3 inhibitor. Even though PDE3A appears to be the main 
isoform responsible for thrombin-induced platelet activation 
(21), other PDE isoforms or isoenzymes likely contribute to 
activation (15). Cilastazol showed a similar partial inhibition of 
thrombin-stimulated P-selectin expression in human platelets at 
comparable concentrations to that used herein (22). Trequinsin, 
another PDE3 inhibitor, also inhibits thrombin-induced activa-
tion of equine platelets (18–20), however, to our knowledge, this 
is the first study testing cilostazol for platelet inhibitory effects in 
horses. Of the two tested PDE inhibitors, only cilostazol has been 
used as a thromboprophylactic drug in humans (34), with IBMX 
being largely an in vitro or ex vivo experimental tool. Since we and 
others have shown that the weaker non-selective PDE inhibitors, 
theophylline and pentoxifylline, are ineffective at inhibiting plate-
let activation when administered to horses (see text footnote 1) or 
tested ex vivo (20, 35), cilostazol has potential as a PDE inhibitor 
in horses. Aside from its antiplatelet effects, cilostazol also acts as 
vasodilator (36). Thus, this drug may have useful rheologic effects 
in conditions other than EHV-1 infection, such as recurrent 
airway obstruction and laminitis (37, 38).
We observed that the DMSO diluent for the PDE inhibitors 
enhanced microvesiculation or fragmentation of equine platelets 
in the presence of EHV-1, but not thrombin. The absence of this 
effect in thrombin-stimulated platelets suggests that it is not a 
consequence of activation per se, but requires the presence of the 
virus. The reason for this finding is unknown, but it is possible 
that DMSO alters the platelet membrane, rendering it more 
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